Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Mayo Clinic Cancer Center Support Grant Renewed By NCI, Comprehensive Status Extended
The Mayo Clinic Cancer Center (MCCC) received an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center, according to Robert Diasio, M.D., the center"s director. Mayo Clinic has the only NCI-designated comprehensive cancer center conducting research at three distinct locations across the United States.

Studying The Effects Of Early Child Abuse: $2.25 Million Grant
This summer, the University of Rochester"s Mt. Hope Family Center will begin a large-scale, comprehensive study of the effects of child abuse. Funded by the National Institute of Mental Health, the five-year, $2.25 million research project aims to understand how a complex host of factors - from genetics and family environment to hormonal regulation, personality traits, and brain activity - influence the well-being and mental health of children who have experienced child maltreatment.
News of the day
TB -- Hiding In Plain Sight
Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.
Public Health

Ancora Pharmaceuticals Awarded National Institute Of Health Grant For Continued Malaria Vaccine Research

With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA). The $530,000 Phase I SBIR grant is the third NIH grant Ancora has received. In 2005, the pharmaceutical company was awarded a $3.3 million grant from NIH to develop their current cerebral malaria vaccine candidate. Scientific evidence indicates that severe malarial disease results from the downstream effects of a toxin generated by the malaria parasite. This toxin gives rise to the same clinical manifestations observed in both CM and SMA, leading to the possibility that Ancora"s first vaccine candidate could be successfully used for both. Malaria afflicts up to ten percent of the global population resulting in between two and three million deaths per year. Because of global warming, the World Health Organization (WHO) has predicted that 50 percent of the population will be at risk of this disease by 2010. This latest grant demonstrates NIH"s continued confidence in Ancora"s ability to create cost-effective vaccines utilizing carbohydrate synthesis. The company"s breakthrough method of producing synthetic carbohydrates allows for approaches to bacterial, parasitic, and viral infectious diseases previously unattainable. Ancora Pharmaceuticals is a private venture-backed biopharmaceutical company based in Medford, Massachusetts focused on developing immune system modulation therapeutics using synthetic carbohydrates. Ancora"s automated carbohydrate synthesizer is internationally recognized as the most advanced in the world. Synthetic carbohydrate therapeutics represents an untapped opportunity within the pharmaceutical industry to develop promising vaccines against some of today"s worst infectious diseases. Ancora Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009